Exact Sciences Corp (EXAS) Financials
Newest figures come from the 10-K for FY2025, filed Feb 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EXAS SEC filings page.
Exact Sciences Corp (EXAS) reported $3.2B in revenue for fiscal year 2025, up 17.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Exact Sciences is turning growth into cash, but accounting losses and a debt-heavier balance sheet remain part of how it operates.
FY2025 paired operating cash flow of$491M with a net loss of$208M , showing that reported earnings were depressed by items that did not reduce current-period cash to the same extent. After$135M of capital spending, free cash flow reached$357M , indicating reinvestment consumed only a minority of internally generated cash.
Gross margin held near
A current ratio of 2.4x in FY2025 indicates reported short-term assets remained well above near-term obligations. Yet debt-to-equity rose to 1.4x from 0.0x in FY2023, so improving cash generation has coincided with a materially more leveraged capital structure.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Exact Sciences Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Exact Sciences Corp has an operating margin of -6.3%, meaning the company loses $6 on every $100 of revenue. This results in a profitability score of 24/100. This is up from -38.0% the prior year.
Exact Sciences Corp's revenue surged 17.7% year-over-year to $3.2B, reflecting rapid business expansion. This strong growth earns a score of 74/100.
Exact Sciences Corp has a moderate D/E ratio of 1.44. This balance of debt and equity financing earns a leverage score of 39/100.
With a current ratio of 2.43, Exact Sciences Corp holds $2.43 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 69/100.
Exact Sciences Corp has a free cash flow margin of 11.0%, earning a moderate score of 52/100. The company generates positive cash flow after capital investments, but with room for improvement.
Exact Sciences Corp posts a -8.7% return on equity (ROE), meaning it loses $9 for every $100 of shareholders' equity. This results in a returns score of 27/100. This is up from -42.8% the prior year.
Exact Sciences Corp scores 2.97, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($20.0B) relative to total liabilities ($3.5B). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Exact Sciences Corp passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Exact Sciences Corp reported a net loss of $207.9M while generating $491.4M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Exact Sciences Corp reported an operating loss of $206.3M against $32.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Exact Sciences Corp generated $878.4M in revenue in Q4 2025. This represents an increase of 23.1% from the same quarter a year earlier. Against the prior quarter it is up 3.2%.
Exact Sciences Corp's EBITDA was -$19.7M in Q4 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 97.6% from the same quarter a year earlier. Against the prior quarter it is down 165.0%.
Exact Sciences Corp reported -$86.0M in net income in Q4 2025. This represents an increase of 90.1% from the same quarter a year earlier. Against the prior quarter it is down 338.7%.
Exact Sciences Corp earned -$0.45 per diluted share (EPS) in Q4 2025. This represents an increase of 90.4% from the same quarter a year earlier. Against the prior quarter it is down 350.0%.
Cash & Balance Sheet
Exact Sciences Corp generated $120.4M in free cash flow in Q4 2025, representing cash available after capex. This represents an increase of 1020.7% from the same quarter a year earlier. Against the prior quarter it is down 36.6%.
Exact Sciences Corp held $956.0M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Margins & Returns
Exact Sciences Corp's gross margin was 70.1% in Q4 2025, indicating the percentage of revenue retained after direct costs. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.5 percentage points.
Exact Sciences Corp's operating margin was -9.4% in Q4 2025, reflecting core business profitability. Against the prior quarter it is down 6.4 percentage points. No change is given against Q4 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Exact Sciences Corp's net profit margin was -9.8% in Q4 2025, showing the share of revenue converted to profit. Against the prior quarter it is down 7.5 percentage points. No change is given against Q4 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Exact Sciences Corp's ROE was -3.6% in Q4 2025, measuring profit generated per dollar of shareholder equity. This is up 32.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.8 percentage points.
Capital Allocation
Exact Sciences Corp invested $191.5M in research and development in Q4 2025. This represents an increase of 96.0% from the same quarter a year earlier. Against the prior quarter it is up 63.3%.
Exact Sciences Corp invested $31.2M in capex in Q4 2025, funding long-term assets and infrastructure. This represents a decrease of 14.0% from the same quarter a year earlier. Against the prior quarter it is up 4.5%.
Not reported for Q4 2025.
EXAS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $878.4M+23.1% | $850.7M+20.0% | $811.1M+16.0% | $706.8M+10.9% | $713.4M+10.3% | $708.7M+12.8% | $699.3M+12.4% | $637.5M+5.8% |
| Cost of Revenue | $262.6M+18.9% | $266.8M+22.9% | $248.6M+17.9% | $206.2M+7.9% | $220.8M+14.4% | $217.2M+14.7% | $210.9M+18.7% | $191.2M+7.7% |
| Gross Profit | $615.8M+25.0% | $583.9M+18.8% | $562.5M+15.2% | $500.5M+12.1% | $492.6M+8.5% | $491.5M+11.9% | $488.3M+9.9% | $446.3M+5.1% |
| R&D Expenses | $191.5M+96.0% | $117.3M+15.6% | $108.9M-10.1% | $105.3M-5.0% | $97.7M-15.2% | $101.5M-9.1% | $121.1M+16.1% | $110.9M+15.9% |
| SG&A Expenses | $218.0M+14.1% | $241.4M+24.7% | $208.6M+17.5% | $220.7M+0.5% | $191.1M-2.7% | $193.5M-0.4% | $177.5M-17.6% | $219.7M+13.1% |
| Operating Income | -$82.6M+90.6% | -$25.5M+35.2% | -$2.1M+91.8% | -$96.0M+10.0% | -$876.4M-1191.8% | -$39.4M-675.3% | -$26.3M+65.9% | -$106.7M-38.4% |
| EBITDA | -$19.7M+97.6% | $30.4M+98.4% | $53.2M+98.8% | -$41.9M+20.5% | -$823.2M-5922.4% | $15.3M-74.1% | $26.7M+200.9% | -$52.7M-92.9% |
| Interest Expense | $5.0M | $9.8M+1.9% | $9.8M+8960.4% | $8.3M+32.5% | N/A | $9.6M+222.1% | -$111K+98.6% | $6.2M+52.1% |
| Income Tax | $872K+107.7% | $1.8M+127.4% | $1.1M-22.9% | $224K-87.6% | -$11.4M-1765.7% | $808K+224.5% | $1.5M+32.2% | $1.8M+9.0% |
| Net Income | -$86.0M+90.1% | -$19.6M+48.8% | -$1.2M+92.5% | -$101.2M+8.2% | -$864.6M-1637.3% | -$38.2M-4915.6% | -$15.8M+80.5% | -$110.2M-48.7% |
| EPS (Basic) | -$0.45+90.4% | -$0.10+52.4% | -$0.01+88.9% | -$0.54+10.0% | -$4.67-1629.6% | -$0.21 | -$0.09+80.0% | -$0.60-42.9% |
| EPS (Diluted) | -$0.45+90.4% | -$0.10+52.4% | -$0.01+88.9% | -$0.54+10.0% | -$4.67-1629.6% | -$0.21 | -$0.09+80.0% | -$0.60-42.9% |
| Diluted Shares (Avg) | N/A | 189M+2.4% | 189M+2.5% | 187M+2.4% | 185M+2.3% | 185M+0.4% | 184M+2.3% | 182M+2.1% |
EXAS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.9B-1.1% | $5.9B-12.6% | $5.8B-13.1% | $5.7B-10.4% | $5.9B-8.4% | $6.7B+5.1% | $6.7B+5.0% | $6.4B+1.1% |
| Current Assets | $1.6B-1.0% | $1.6B+3.8% | $1.5B+3.8% | $1.4B+22.3% | $1.6B+31.6% | $1.5B+33.5% | $1.5B+23.7% | $1.1B+2.6% |
| Cash & Equivalents | $956.0M+59.1% | $789.0M+34.0% | $657.1M+23.9% | $347.1M-0.1% | $600.9M-0.7% | $588.8M-1.0% | $530.2M-12.3% | $347.5M-17.5% |
| Short-Term Investments | $8.7M-98.0% | $214.1M-50.5% | $201.3M-51.7% | $439.0M+44.1% | $437.1M+153.8% | $432.3M+209.2% | $416.6M+143.1% | $304.6M+9.9% |
| Inventory | $166.2M+2.4% | $164.8M+20.3% | $171.5M+34.6% | $176.6M+37.4% | $162.4M+27.4% | $137.0M+3.1% | $127.4M-2.6% | $128.5M+3.6% |
| Accounts Receivable | $298.7M+20.0% | $306.1M+15.6% | $353.3M+33.9% | $279.8M+16.3% | $249.0M+22.3% | $264.8M+32.8% | $263.9M+48.0% | $240.6M+31.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $2.4B+0.1% | $2.4B0.0% | $2.4B0.0% | $2.4B0.0% | $2.4B0.0% | $2.4B0.0% | $2.4B+0.9% | $2.4B+0.9% |
| Total Liabilities | $3.5B-1.9% | $3.4B-3.9% | $3.3B-4.4% | $3.3B+2.2% | $3.5B+6.0% | $3.5B+7.2% | $3.5B+5.5% | $3.2B-0.1% |
| Current Liabilities | $641.2M-12.4% | $584.3M-19.3% | $521.9M-21.9% | $502.5M-26.7% | $732.2M+42.3% | $723.7M+51.9% | $668.6M+37.0% | $685.1M+86.5% |
| Non-Current Liabilities | $2.8B+0.9% | $2.8B0.0% | $2.8B-0.2% | $2.8B+9.9% | $2.8B-0.6% | $2.8B-0.3% | $2.8B+0.1% | $2.6B-11.1% |
| Total Equity | $2.4B0.0% | $2.5B-22.1% | $2.5B-22.6% | $2.4B-23.5% | $2.4B-23.6% | $3.2B+2.9% | $3.2B+4.4% | $3.1B+2.4% |
| Retained Earnings | -$4.7B-4.6% | -$4.6B-27.2% | -$4.6B-28.0% | -$4.6B-28.5% | -$4.5B-29.7% | -$3.6B-6.3% | -$3.6B-5.1% | -$3.6B-7.2% |
Not reported in any period shown, so not listed: Long-Term Debt.
EXAS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $151.7M+222.3% | $219.9M+58.5% | $89.0M-16.9% | $30.8M+137.4% | $47.1M-32.3% | $138.7M+469.4% | $107.1M+6.6% | -$82.3M-115.4% |
| Depreciation & Amortization | $56.4M+6.0% | $55.9M+2.2% | $55.3M+4.3% | $54.1M+0.2% | $53.1M-1.9% | $54.7M+4.6% | $53.0M+5.1% | $53.9M+8.4% |
| Stock-Based Compensation | N/A | $51.6M+5.7% | $55.8M-1.4% | $54.6M-9.5% | N/A | $48.8M-21.1% | $56.6M-8.3% | $60.4M+22.9% |
| Capital Expenditures | $31.2M-14.0% | $29.9M+14.3% | $42.3M+18.1% | $31.2M-17.2% | $36.3M+4.0% | $26.2M+3.9% | $35.9M+3.3% | $37.6M+28.2% |
| Free Cash Flow | $120.4M+1020.7% | $190.0M+68.8% | $46.7M-34.4% | -$365K+99.7% | $10.7M-69.0% | $112.6M+13727.2% | $71.2M+8.4% | -$120.0M-77.5% |
| Investing Cash Flow | $91.1M+317.6% | -$86.5M-5.8% | $224.9M+252.9% | -$34.4M+79.9% | -$41.9M+37.3% | -$81.7M-147.9% | -$147.1M-321.3% | -$171.4M-306.7% |
| Financing Cash Flow | -$75.9M-822.7% | -$1.5M-577.9% | -$4.5M-102.0% | -$256.2M-8433.3% | $10.5M+4.6% | -$226K-345.7% | $224.6M+1300.2% | -$3.0M-102.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EXAS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.1%+1.1pp | 68.6%-0.7pp | 69.3%-0.5pp | 70.8%+0.8pp | 69.0%-1.1pp | 69.3%-0.5pp | 69.8%-1.6pp | 70.0%-0.5pp |
| Operating Margin | -9.4% | -3.0%+2.6pp | -0.3%+3.5pp | -13.6%+3.2pp | -122.8% | -5.6%-6.7pp | -3.8%+8.6pp | -16.7%-3.9pp |
| Net Margin | -9.8% | -2.3%+3.1pp | -0.1%+2.1pp | -14.3%+3.0pp | -121.2% | -5.4%-5.5pp | -2.3%+10.8pp | -17.3%-5.0pp |
| Return on Equity | -3.6%+32.4pp | -0.8%+0.4pp | -0.1%+0.5pp | -4.2%-0.7pp | -36.0%-34.4pp | -1.2%-1.2pp | -0.5%+2.1pp | -3.5%-1.1pp |
| Return on Assets | -1.5%+13.1pp | -0.3%+0.2pp | 0.0%+0.2pp | -1.8%0.0pp | -14.6%-13.8pp | -0.6%-0.6pp | -0.2%+1.0pp | -1.7%-0.5pp |
| Current Ratio | 2.43+0.3x | 2.72+0.6x | 2.89+0.7x | 2.73+1.1x | 2.15-0.2x | 2.12-0.3x | 2.17-0.2x | 1.64-1.3x |
| Debt-to-Equity | 1.440.0x | 1.36+0.3x | 1.35+0.3x | 1.38+0.3x | 1.47+1.5x | 1.100.0x | 1.090.0x | 1.040.0x |
| Asset Turnover | 0.150.0x | 0.140.0x | 0.140.0x | 0.120.0x | 0.120.0x | 0.100.0x | 0.100.0x | 0.100.0x |
| FCF Margin | 13.7%+12.2pp | 22.3%+6.5pp | 5.8%-4.4pp | -0.1%+18.8pp | 1.5%-3.8pp | 15.9%+16.0pp | 10.2%-0.4pp | -18.8%-7.6pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Exact Sciences Corp EXAS | FY2025 | $3.2B | -$207.9M | -6.4% | $20.0B | 48/100 |
| Illumina Inc ILMN | FY2025 | $4.3B | $850.0M | 19.6% | $40.4B | 44/100 |
| Medpace Holdings, Inc. MEDP | FY2025 | $2.5B | $451.1M | 17.8% | $16.9B | 62/100 |
| Icon Plc ICLR | FY2025 | $8.3B | $229.3M | 2.8% | $12.7B | 45/100 |
| Waters Corp WAT | FY2025 | $3.2B | $642.6M | 20.3% | $42.8B | 71/100 |
Where Exact Sciences Corp Ranks
Frequently Asked Questions
What is Exact Sciences Corp's annual revenue?
Exact Sciences Corp (EXAS) reported $3.2B in total revenue for fiscal year 2025. This represents a 17.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Exact Sciences Corp's revenue growing?
Exact Sciences Corp (EXAS) revenue grew by 17.7% year-over-year, from $2.8B to $3.2B in fiscal year 2025.
Is Exact Sciences Corp profitable?
No, Exact Sciences Corp (EXAS) reported a net income of -$207.9M in fiscal year 2025, with a net profit margin of -6.4%.
What is Exact Sciences Corp's EBITDA?
Exact Sciences Corp (EXAS) had EBITDA of $21.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Exact Sciences Corp's gross margin?
Exact Sciences Corp (EXAS) had a gross margin of 69.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Exact Sciences Corp's operating margin?
Exact Sciences Corp (EXAS) had an operating margin of -6.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Exact Sciences Corp's net profit margin?
Exact Sciences Corp (EXAS) had a net profit margin of -6.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Exact Sciences Corp's return on equity (ROE)?
Exact Sciences Corp (EXAS) has a return on equity of -8.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Exact Sciences Corp's free cash flow?
Exact Sciences Corp (EXAS) generated $356.8M in free cash flow during fiscal year 2025. This represents a 378.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Exact Sciences Corp's operating cash flow?
Exact Sciences Corp (EXAS) generated $491.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Exact Sciences Corp's total assets?
Exact Sciences Corp (EXAS) had $5.9B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Exact Sciences Corp's capital expenditures?
Exact Sciences Corp (EXAS) invested $134.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Exact Sciences Corp spend on research and development?
Exact Sciences Corp (EXAS) invested $523.0M in research and development during fiscal year 2025.
What is Exact Sciences Corp's current ratio?
Exact Sciences Corp (EXAS) had a current ratio of 2.43 as of fiscal year 2025, which is generally considered healthy.
What is Exact Sciences Corp's debt-to-equity ratio?
Exact Sciences Corp (EXAS) had a debt-to-equity ratio of 1.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Exact Sciences Corp's return on assets (ROA)?
Exact Sciences Corp (EXAS) had a return on assets of -3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Exact Sciences Corp's Altman Z-Score?
Exact Sciences Corp (EXAS) has an Altman Z-Score of 2.97, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Exact Sciences Corp's Piotroski F-Score?
Exact Sciences Corp (EXAS) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Exact Sciences Corp's earnings high quality?
Exact Sciences Corp (EXAS) reported a net loss of $207.9M while generating $491.4M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Exact Sciences Corp cover its interest payments?
Exact Sciences Corp (EXAS) reported an operating loss of $206.3M against $32.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Exact Sciences Corp?
Exact Sciences Corp (EXAS) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.